NIH-funded research Fellowship grant

Investigating how a specific enzyme affects cocaine use disorder in brain cells

Official title: Defining the cell-type specific role of histone acetyltransferase KAT2a in nucleus accumbens D1 medium spiny neurons as a driver of cocaine use disorder

Funded at Vanderbilt University · NIH-10830266 · Data updated 2026-11-12

This study is looking at how a certain enzyme in brain cells might influence addiction to cocaine, with the hope of finding new ways to help people struggling with cocaine use disorder.

More Cocaine Use Disorder research and trials

Quick facts

Grant typeFellowship grant
Study typeNIH-funded research
Funding institutionVanderbilt University
NIH-funded
Lab location1 site (Nashville, UNITED STATES)
Project startAugust 1, 2023
Project endJuly 31, 2027
Funding year2024
Award (this year)$34,285
NIH project number5F31DA058450-02
Project IDNIH-10830266 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals struggling with cocaine use disorder who may benefit from new treatment options.

Less likely to help

Patients who do not have a history of cocaine use or those with other substance use disorders unrelated to cocaine may not benefit from this research.

What this research studies

This research focuses on understanding the role of a specific enzyme, KAT2a, in brain cells that are involved in cocaine use disorder (CUD). By studying how this enzyme affects the behavior of dopamine receptor-expressing neurons in the nucleus accumbens, the research aims to uncover the molecular mechanisms that lead to addiction. The approach includes detailed proteomic and bioinformatic analyses to identify changes in gene expression related to cocaine exposure. The findings could provide insights into potential new treatments for CUD.

Why it matters

Potential benefit: If successful, this research could lead to the development of new pharmacotherapies for cocaine use disorder.

How similar studies have gone: Previous research has shown promising results in understanding the molecular mechanisms of addiction, but this specific approach focusing on KAT2a is relatively novel.

Where this research is happening

  • Vanderbilt University
    Nashville, United States
    Active

Researchers

  • Principal investigator: Emerson, Soren D — Vanderbilt University
  • Study coordinator: Emerson, Soren D

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.